{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:31:34Z","timestamp":1790422294633,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100023448","name":"Robert Koch-Institut","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Untersucht wurden die Auswirkungen der HIV-Pr\u00e4expositionsprophylaxe (PrEP) als neue Leistung der gesetzlichen Krankenversicherung (GKV) auf das Infektionsgeschehen von HIV und anderen sexuell \u00fcbertragbaren Infektionen (STI) in Deutschland. Zus\u00e4tzlich wurden PrEP-Bedarfe sowie Zugangsbarrieren analysiert.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methoden<\/jats:title>\n                <jats:p>Im Rahmen des Evaluationsprojektes wurden folgende Daten ausgewertet: HIV- und Syphilis-Meldedaten und erweiterte Surveillance des Robert Koch-Instituts (RKI), Apothekenabrechnungsdaten, GKV-Daten, PrEP-Gebrauch in HIV-Schwerpunktzentren, Checkpoint\u2011, BRAHMS- und PrApp-Studie sowie ein Community-Beirat.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Die PrEP-Nutzenden waren zum gr\u00f6\u00dften Teil m\u00e4nnlich (98\u201399\u202f%), zum Gro\u00dfteil im Alter zwischen 25\u201345\u00a0Jahren und \u00fcberwiegend deutscher Staatsangeh\u00f6rigkeit oder Herkunft (67\u201382\u202f%). Der Gro\u00dfteil z\u00e4hlte zur Gruppe der M\u00e4nner, die Sex mit M\u00e4nnern haben (99\u202f%). In Bezug auf HIV-Infektionen zeigte sich die PrEP als hocheffektiv. Es fanden nur vereinzelt HIV-Infektionen statt (HIV-Inzidenzrate 0,08\/100 Personenjahre), in den meisten F\u00e4llen war der vermutete Grund eine geringe Adh\u00e4renz. Die Inzidenzen von Chlamydien, Gonorrh\u00f6 und Syphilis nahmen nicht zu, sondern blieben nahezu gleich oder gingen sogar zur\u00fcck. Es zeigte sich Informationsbedarf zur PrEP f\u00fcr Personen in trans*\/nichtbin\u00e4ren Communitys, Sexarbeitende, Migrant*innen und Drogengebrauchende. Notwendig w\u00e4ren bedarfsgerechte Angebote f\u00fcr Zielgruppen mit erh\u00f6htem HIV-Risiko.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>Die PrEP erwies sich als eine sehr wirkungsvolle HIV-Pr\u00e4ventionsmethode. Die teils bef\u00fcrchteten indirekten negativen Einfl\u00fcsse auf STI-Raten wurden in dieser Untersuchung nicht best\u00e4tigt. Aufgrund der zeitlichen \u00dcberschneidung mit den Eind\u00e4mmungsma\u00dfnahmen w\u00e4hrend der COVID-19-Pandemie w\u00e4re f\u00fcr eine abschlie\u00dfende Beurteilung ein l\u00e4ngerer Beobachtungszeitraum w\u00fcnschenswert.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00103-023-03733-0","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T10:02:01Z","timestamp":1689156121000},"page":"1008-1018","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Evaluation der Einf\u00fchrung der HIV-Pr\u00e4expositionsprophylaxe als Leistung der gesetzlichen Krankenversicherung (EvE\u2011PrEP)","Evaluating the introduction of HIV pre-exposure prophylaxis as a\u00a0benefit of statutory health insurance (EvE-PrEP)"],"prefix":"10.1007","volume":"66","author":[{"given":"Daniel","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kollan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knud","family":"Schewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Hanhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"R\u00fcsenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Friebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Schikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne Barbara","family":"Schink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Koppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Streeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ottensmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"an der Heiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Bannert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaline","family":"M\u2019Bayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Ceres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Sweers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel Jeremias","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Tietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Danan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Bendig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kloep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Valbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bartmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"NEPOS Studiengruppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"3733_CR1","unstructured":"Sozialgesetzbuch V, \u00a7 20j Abs. 5. 2019."},{"issue":"10013","key":"3733_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","volume":"387","author":"S McCormack","year":"2016","unstructured":"McCormack\u00a0S, Dunn\u00a0D, Desai\u00a0M, Dolling\u00a0D, Gafos\u00a0M, Gilson\u00a0R et al (2016) Pre-exposure prophylaxis to prevent the acquisition of HIV\u20111 infection (PROUD): effectiveness results from the pilot phase of a\u00a0pragmatic open-label randomised trial. Lancet 387(10013):53\u201360","journal-title":"Lancet"},{"issue":"8","key":"3733_CR3","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1016\/S2352-3018(21)00074-6","volume":"8","author":"AE Grulich","year":"2021","unstructured":"Grulich\u00a0AE, Jin\u00a0F, Bavinton\u00a0BR, Yeung\u00a0B, Hammoud\u00a0MA, Amin\u00a0J et al (2021) Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study. Lancet HIV 8(8):e486\u2013e494","journal-title":"Lancet HIV"},{"issue":"23","key":"3733_CR4","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","volume":"373","author":"J-M Molina","year":"2015","unstructured":"Molina\u00a0J\u2011M, Capitant\u00a0C, Spire\u00a0B, Pialoux\u00a0G, Cotte\u00a0L, Charreau\u00a0I et al (2015) On-demand preexposure prophylaxis in men at high risk for HIV\u20111 infection. N\u00a0Engl J Med 373(23):2237\u20132246","journal-title":"N Engl J Med"},{"issue":"1","key":"3733_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/jamainternmed.2015.4683","volume":"176","author":"AY Liu","year":"2016","unstructured":"Liu\u00a0AY, Cohen\u00a0SE, Vittinghoff\u00a0E, Anderson\u00a0PL, Doblecki-Lewis\u00a0S, Bacon\u00a0O et al (2016) Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med 176(1):75\u201384","journal-title":"JAMA Intern Med"},{"issue":"10","key":"3733_CR6","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/cid\/civ778","volume":"61","author":"JE Volk","year":"2015","unstructured":"Volk\u00a0JE, Marcus\u00a0JL, Phengrasamy\u00a0T, Blechinger\u00a0D, Nguyen\u00a0DP, Follansbee\u00a0S et\u00a0al (2015) No new HIV infections with increasing use of HIV preexposure prophylaxis in a\u00a0clinical practice setting. Clin Infect Dis 61(10):1601\u20131603","journal-title":"Clin Infect Dis"},{"issue":"9","key":"3733_CR7","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","volume":"14","author":"RM Grant","year":"2014","unstructured":"Grant\u00a0RM, Anderson\u00a0PL, McMahan\u00a0V, Liu\u00a0A, Amico\u00a0KR, Mehrotra\u00a0M et al (2014) Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a\u00a0cohort study. Lancet Infect Dis 14(9):820\u2013829","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"3733_CR8","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1093\/cid\/ciz1229","volume":"71","author":"DK Smith","year":"2020","unstructured":"Smith\u00a0DK, Sullivan\u00a0PS, Cadwell\u00a0B, Waller\u00a0LA, Siddiqi\u00a0A, Mera-Giler\u00a0R et al (2020) Evidence of an association of increases in pre-exposure prophylaxis coverage with decreases in human immunodeficiency virus diagnosis rates in the United States, 2012\u20132016. Clin Infect Dis 71(12):3144\u20133151","journal-title":"Clin Infect Dis"},{"key":"3733_CR9","unstructured":"BMV-Ae_Anlage_33_PreP_24-7-2019.pdf [Internet]. Available from: https:\/\/www.gkv-spitzenverband.de\/media\/dokumente\/krankenversicherung_1\/aerztliche_versorgung\/bundesmantelvertrag_1\/bmv_anlagen\/BMV-Ae_Anlage_33_PreP_24-7-2019.pdf (letzter Zugriff am 3. Apr. 2023)"},{"key":"3733_CR10","unstructured":"\u00d6ffentliche Bekanntmachung des Bundesministeriums f\u00fcr Gesundheit (BMG) zur Evaluation der Einf\u00fchrung der medikament\u00f6sen Pr\u00e4expositionsprophylaxe (PrEP) als Leistung der Gesetzlichen Krankenversicherung, (2019)."},{"key":"3733_CR11","first-page":"24","volume":"04\/2019","author":"D Schmidt","year":"2019","unstructured":"Schmidt\u00a0D, R\u00fcsenberg\u00a0R (2019) HIV-Pr\u00e4expositionsprophylaxe: Einf\u00fchrung der PrEP wird wissenschaftlich begleitet. HIV More 04\/2019:24\u201325","journal-title":"HIV More"},{"key":"3733_CR12","first-page":"3","volume":"06\/2021","author":"D Schmidt","year":"2021","unstructured":"Schmidt\u00a0D, Merbach\u00a0M, Friebe\u00a0M, Hanhoff\u00a0N, R\u00fcsenberg\u00a0R, Schewe\u00a0K (2021) Wissenschaftliche Begleitung und Evaluation der HIV-PrEP als Leistung der gesetzlichen Krankenversicherung \u2013 das Projekt EvE-PrEP in Zeiten der SARS-CoV-2-Pandemie. Epidemiol Bull 06\/2021:3\u201312","journal-title":"Epidemiol Bull"},{"key":"3733_CR13","doi-asserted-by":"crossref","unstructured":"Schmidt D Projekthomepage: Evaluation der Einf\u00fchrung der HIV-Pr\u00e4expositionsprophylaxe als Leistung der Gesetzlichen Krankenversicherung (EvE-PrEP): Robert Koch-Institut. https:\/\/www.rki.de\/eve-prep. Zugegriffen: 3. Apr. 2023","DOI":"10.1007\/s00103-023-03733-0"},{"key":"3733_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s10389-022-01699-y","volume-title":"Analysis of HIV pre-exposure prophylaxis (PrEP) needs and PrEP use among men who have sex with men in","author":"U Marcus","year":"2022","unstructured":"Marcus U, Schmidt D, Schink SB, Koppe U (2022) Analysis of HIV pre-exposure prophylaxis (PrEP) needs and PrEP use among men who have sex with men in Germany. J Public Healt. https:\/\/doi.org\/10.1007\/s10389-022-01699-y"},{"key":"3733_CR15","unstructured":"Mitglieder und Versicherte je Krankenkasse. https:\/\/www.krankenkasseninfo.de\/zahlen-fakten\/mitgliederzahlen\/. Zugegriffen: 3. Apr. 2023"},{"issue":"14","key":"3733_CR16","doi-asserted-by":"publisher","first-page":"2100591","DOI":"10.2807\/1560-7917.ES.2022.27.14.2100591","volume":"27","author":"H Streeck","year":"2022","unstructured":"Streeck\u00a0H, Jansen\u00a0K, Crowell\u00a0TA, Esber\u00a0A, Jessen\u00a0HK, Cordes\u00a0C et al (2022) HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a\u00a0high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019. Euro Surveill 27(14):2100591","journal-title":"Euro Surveill"},{"key":"3733_CR17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s15010-022-01919-3","volume":"51","author":"D Schmidt","year":"2023","unstructured":"Schmidt D, Kollan C, Bartmeyer B et al (2023) Low incidence of HIV infection and decreasing incidence of sexually transmitted infections among PrEP users in 2020 in Germany. Infection 51:665\u2013678. https:\/\/doi.org\/10.1007\/s15010-022-01919-3","journal-title":"Infection"},{"key":"3733_CR18","first-page":"3","volume":"44\/2021","author":"D Schmidt","year":"2021","unstructured":"Schmidt\u00a0D, Schikowski\u00a0T, Friebe\u00a0M, Kollan\u00a0C, Bartmeyer\u00a0B, Bremer\u00a0V et al (2021) PrEP-Evaluation EvE-PrEP \u2013 Ergebnisse einer Befragung zum PrEP-Versorgungsgeschehen in HIV-Schwerpunktzentren des dagn\u00e4-Netzwerks. Epidemiol Bull 44\/2021:3\u201312","journal-title":"Epidemiol Bull"},{"key":"3733_CR19","first-page":"28","volume":"4","author":"D Schmidt","year":"2021","unstructured":"Schmidt D, Schikowski T, Friebe M, Kollan C, Bartmeyer B, Bremer V et al (2021) PrEP-Evaluation (EvE-PrEP) \u2013 Ergebnisse einer Befragung zum PrEP-Versorgungsgeschehen in HIV-Schwerpunktzentren des dagn\u00e4-Netzwerks. HIV More 4:28\u201331","journal-title":"HIV More"},{"key":"3733_CR20","unstructured":"Schmidt D (2020) Bericht zur 1. Sitzung der Community-Vertretungen zur Evaluation der Einf\u00fchrung der medikament\u00f6sen HIV-Pr\u00e4expositionsprophylaxe als Leistung der GKV (EvE-PrEP). Berlin: Robert Koch-Institut. https:\/\/www.rki.de\/DE\/Content\/InfAZ\/H\/HIVAIDS\/Bericht_Sitzung-1_Community-Vertretungen_EvE-PrEP.pdf?__blob=publicationFile. Zugegriffen: 3. Apr. 2023"},{"key":"3733_CR21","unstructured":"Schmidt D (2020) Bericht zur 2. virtuellen Sitzung der Community-Vertretungen zur Evaluation der Einf\u00fchrung der medikament\u00f6sen HIV-Pr\u00e4expositionsprophylaxe als Leistung der GKV (EvE-PrEP). Berlin: Robert Koch-Institut. https:\/\/www.rki.de\/DE\/Content\/InfAZ\/H\/HIVAIDS\/Bericht_Sitzung-2_Community-Vertretungen_EvE-PrEP.pdf?__blob=publicationFile. Zugegriffen: 3. Apr. 2023"},{"key":"3733_CR22","unstructured":"Schmidt D (2021) Bericht zur 3. virtuellen Sitzung der Community-Vertretungen zur Evaluation der Einf\u00fchrung der medikament\u00f6sen HIV-Pr\u00e4expositionsprophylaxe als Leistung der GKV (EvE-PrEP). Berlin: Robert Koch-Institut. https:\/\/www.rki.de\/DE\/Content\/InfAZ\/H\/HIVAIDS\/Studien\/EvE-PrEP\/Bericht_Community-Sitzung-3.pdf?__blob=publicationFile. Zugegriffen: 3. Apr. 2023"},{"key":"3733_CR23","doi-asserted-by":"crossref","unstructured":"Schmidt D, Bartmeyer B, Bremer V, Friebe M, Schikowski T, Schink SB et al (2022) Abschlussbericht \u2013 Evaluation der Einf\u00fchrung der HIV-Pr\u00e4expositionsprophylaxe als Leistung der Gesetzlichen Krankenversicherung (EvE-PrEP). Robert Koch-Institut. https:\/\/www.rki.de\/DE\/Content\/InfAZ\/H\/HIVAIDS\/Abschlussbericht_EvE-PrEP.pdf?__blob=publicationFile. Zugegriffen: 3. Apr. 2023","DOI":"10.1007\/s00103-023-03733-0"},{"issue":"1","key":"3733_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/sexes3010014","volume":"3","author":"MN Appenroth","year":"2022","unstructured":"Appenroth\u00a0MN, Marcus\u00a0U, Albrecht\u00a0S, Jansen\u00a0K, Gunsenheimer-Bartmeyer\u00a0B, Bremer\u00a0V et al (2022) Similar sexual behaviour yet different outcomes: comparing trans and gender diverse and Cis PrEP users in Germany based on the outcomes of the Prapp study. Sexes 3(1):178\u2013188","journal-title":"Sexes"},{"key":"3733_CR25","volume-title":"HIV Pre-Exposure prophylaxis (PrEP) use in Germany before and after cost-coverage by statutory health insurances","author":"U Koppe","year":"2021","unstructured":"Koppe\u00a0U, Marcus\u00a0U, Albrecht\u00a0S, Jansen\u00a0K, Gunsenheimer-Bartmeyer\u00a0B, Bremer\u00a0V (2021) HIV Pre-Exposure prophylaxis (PrEP) use in Germany before and after cost-coverage by statutory health insurances. 18th European AIDS Conference (EACS 2021), London"},{"key":"3733_CR26","unstructured":"Schmidt D (2023) PrEP in Deutschland \u2013 Ergebnisse aus PrEP-Evaluation und nationaler PrEP-Surveillance.  11. Deutsch-\u00d6sterreichischer-AIDS-Kongress (D\u00d6AK 2023); 23.3.\u201325.3.2023, Bonn"},{"issue":"10246","key":"3733_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","volume":"396","author":"KH Mayer","year":"2020","unstructured":"Mayer\u00a0KH, Molina\u00a0J\u2011M, Thompson\u00a0MA, Anderson\u00a0PL, Mounzer\u00a0KC, De Wet\u00a0JJ et al (2020) Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a\u00a0randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet 396(10246):239\u2013254","journal-title":"Lancet"},{"key":"3733_CR28","volume-title":"HIV and STI incidence among MSM users and non-users of HIV PrEP in England: results from the Impact trial\u2014Preliminary Report","author":"R Sullivan","year":"2021","unstructured":"Sullivan\u00a0R, Chiavenna\u00a0C, Cartier\u00a0A, Jaffer\u00a0S et al (2021) HIV and STI incidence among MSM users and non-users of HIV PrEP in England: results from the Impact trial\u2014Preliminary Report. 18th European AIDS Conference."},{"issue":"8","key":"3733_CR29","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.1016\/S2352-3018(22)00133-3","volume":"9","author":"J-M Molina","year":"2022","unstructured":"Molina\u00a0J\u2011M, Ghosn\u00a0J, Assoumou\u00a0L, Delaugerre\u00a0C, Algarte-Genin\u00a0M, Pialoux\u00a0G et al (2022) Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a\u00a0prospective observational cohort study. Lancet HIV 9(8):e554\u2013e562","journal-title":"Lancet HIV"},{"issue":"11","key":"3733_CR30","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/S2352-3018(18)30215-7","volume":"5","author":"AE Grulich","year":"2018","unstructured":"Grulich\u00a0AE, Guy\u00a0R, Amin\u00a0J, Jin\u00a0F, Selvey\u00a0C, Holden\u00a0J et al (2018) Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV 5(11):e629\u2013e637","journal-title":"Lancet HIV"},{"key":"3733_CR31","doi-asserted-by":"publisher","unstructured":"an der Heiden M, Marcus U, Kollan C, Schmidt D, Gunsenheimer-Bartmeyer B, Bremer V (2021) Sch\u00e4tzung der Zahl der HIV-Neuinfektionen und der Gesamtzahl von Menschen mit HIV in Deutschland, Stand Ende 2020. Epidemiol Bull 47:3\u201317. https:\/\/doi.org\/10.25646\/9301","DOI":"10.25646\/9301"},{"issue":"9","key":"3733_CR32","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/cid\/ciz552","volume":"70","author":"JA Serpa","year":"2020","unstructured":"Serpa\u00a0JA, Huynh\u00a0GN, Nickell\u00a0JB, Miao\u00a0H (2020) Human immunodeficiency virus pre-exposure prophylaxis and increased incidence of sexually transmitted infections in the United States. Clin Infect Dis 70(9):1884\u20131890","journal-title":"Clin Infect Dis"},{"issue":"14","key":"3733_CR33","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1001\/jama.2019.2947","volume":"321","author":"M Traeger","year":"2019","unstructured":"Traeger\u00a0M, Cornelisse\u00a0V, Asselin\u00a0J, Price\u00a0B, Roth\u00a0N, Willcox\u00a0J et\u00a0al (2019) Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. JAMA 321(14):1380\u20131390","journal-title":"JAMA"},{"issue":"8","key":"3733_CR34","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1016\/S1473-3099(17)30310-9","volume":"17","author":"M Unemo","year":"2017","unstructured":"Unemo\u00a0M, Bradshaw\u00a0CS, Hocking\u00a0JS, de Vries\u00a0HJC, Francis\u00a0SC, Mabey\u00a0D et\u00a0al (2017) Sexually transmitted infections: challenges ahead. Lancet Infect Dis 17(8):e235\u2013e279","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"3733_CR35","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/hiv.13181","volume":"22","author":"C Grimshaw","year":"2021","unstructured":"Grimshaw\u00a0C, Boyd\u00a0L, Smith\u00a0M, Estcourt\u00a0CS, Metcalfe\u00a0R (2021) Evaluation of an inner city HIV pre-exposure prophylaxis service tailored to the needs of people who inject drugs. HIV Med 22(10):965\u2013970","journal-title":"HIV Med"},{"key":"3733_CR36","unstructured":"Schmidt D Projekthomepage: Surveillance der Versorgung mit der HIV-Pr\u00e4expositionsprophylaxe innerhalb der GKV in Deutschland (PrEP-Surv): Robert Koch-Institut. https:\/\/www.rki.de\/hiv-prepsurv. Zugegriffen: 3. Apr. 2023"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-023-03733-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-023-03733-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-023-03733-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T13:03:58Z","timestamp":1693314238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-023-03733-0"}},"subtitle":["Hocheffektiver Schutz vor HIV und keine Zunahme von sexuell \u00fcbertragbaren Infektionen","Highly effective protection against HIV without an increase in sexually transmitted infections"],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["3733"],"URL":"https:\/\/doi.org\/10.1007\/s00103-023-03733-0","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]},"assertion":[{"value":"3 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.\u00a0Schmidt, C.\u00a0Kollan, K.\u00a0Schewe, N.\u00a0Hanhoff, R.\u00a0R\u00fcsenberg, M.\u00a0Friebe, T.\u00a0Schikowski, S.B.\u00a0Schink, U.\u00a0Marcus, K.\u00a0Jansen, H.\u00a0Streeck, P.\u00a0Ottensmeyer, M.\u00a0an der Heiden, N.\u00a0Bannert, R.\u00a0M\u2019Bayo, M.\u00a0Ceres, L.\u00a0Weber, H.\u00a0Sweers, A.J.\u00a0Schmidt, H.\u00a0Tietz, E.\u00a0Danan, J.\u00a0Bendig, S.\u00a0Kloep, A.\u00a0Neumann, F.\u00a0Valbert, J.\u00a0Wasem, B.\u00a0Bartmeyer und V.\u00a0Bremer geben an, dass kein Interessenkonflikt besteht. U.\u00a0Koppe besitzt Anteile an \u201eExchange-traded fund\u201c\u202f=\u2009(ETF-)Fonds, die Aktien von Firmen enthalten k\u00f6nnen, die PrEP entwickeln oder produzieren.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Patient\/-innen liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}